FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2017/10/010115 [Registered on: 16/10/2017] Trial Registered Retrospectively
Last Modified On: 21/09/2021
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Imaging 
Study Design  Non-randomized, Active Controlled Trial 
Public Title of Study   A Safe and Non-invasive Breast Cancer Screening Solution  
Scientific Title of Study   Multicentric Study to evaluate the effectiveness of Thermalytix© (automated thermographic screening algorithms developed by NIRAMAI) as compared to standard screening modalities in subjects who show possible symptoms of suspected breast cancer 
Trial Acronym  SANT17 
Secondary IDs if Any  
Secondary ID  Identifier 
NI-THERMA-01 Version 1.1 Dated July 19th 2017  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Sudhakar S 
Designation  Radiologist 
Affiliation  HCG Cancer Hospital 
Address  Department of Radiology HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar

Bangalore
KARNATAKA
560027
India 
Phone  9008801379  
Fax    
Email  dr_sudhakar79@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Sudhakar S 
Designation  Radiologist 
Affiliation  HCG Cancer Hospital 
Address  Department of Radiology HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar

Bangalore
KARNATAKA
560027
India 
Phone  9008801379  
Fax    
Email  dr_sudhakar79@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Geetha Manjunath 
Designation  Chief Executive Officer 
Affiliation  NIRAMAI Health Analytix Pvt Ltd 
Address  A7-506, Elita Promenade, J P Nagar 7th Phase

Bangalore
KARNATAKA
560078
India 
Phone  9880118379  
Fax    
Email  geetha@niramai.com  
 
Source of Monetary or Material Support  
NIRAMAI Health Analytix Pvt Ltd, A7-506, Elita Promenade, JP Nagar 7th Phase, Bangalore - 560078 
 
Primary Sponsor  
Name  NIRAMAI Health Analytix Pvt Ltd 
Address  A7-506 Elita Promenade J P Nagar 7th Phase Bangalore  
Type of Sponsor  Other [HealthTech Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 2  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr S Sudhakar  HCG Cancer Hospital  HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar Bengaluru Karnataka 560027
Bangalore
KARNATAKA 
08040206000

dr_sudhakar79@yahoo.com 
Dr Venkatraman Bhat  Mazumdar Shaw Medical Center  Mazumdar Shaw Medical Center Narayana Hrudayalaya Limited No 258/A Bommasandra Industrial Area Anekal Taluk Bengaluru 560 099
Bangalore
KARNATAKA 
9481027387

venkatraman.bhat.dr@narayanahealth.org 
 
Details of Ethics Committee  
No of Ethics Committees= 2  
Name of Committee  Approval Status 
HCGCEC  Approved 
NHEC  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied
Modification(s)  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site, (2) ICD-10 Condition: R688||Other general symptoms and signs, possible symptoms of suspected breast cancer ,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Clinical Breast Examination, Sono-Mammography and Mammography  Clinical Breast Examination, Sono-Mammography and Mammography are standard screening modalities for Breast cancer. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Female 
Details  1. Female subjects equal to and above 18 years presenting with the following breast abnormalities:
(1a) Palpable lump, swelling or mass in breast
(1b) Persistent breast pain or tenderness that is unrelated to menstrual cycle
(1c) Nipple is inverted or tender, painful, scaly or with discharge (clear or bloody)
(1d) Skin on breast is dimpled, red, blotchy, pricking, itchy or has change in the texture
(1e) Increase in breast size that is not related to menstrual cycle
(1f) Thickening in or around the breast or underarm area
(1g) Or any other symptoms leading to suspicion of breast cancer
2. Subjects who are willing to give written informed consent for study participation
3. Subjects who are ready to comply with the study related visits and procedures
 
 
ExclusionCriteria 
Details  1. Subjects who are pregnant
2. Subjects who are lactating
3. Subjects who have undergone either lumpectomy or mastectomy
4. Subjects who have undergone Chemotherapy in the last 2 weeks at the time of study enrollment
5. Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1. non-inferiority of sensitivity of Thermalytix to not more than 10% of the standard screening modalities
2.Sensitivity
3. Specificity
4.PPV
5.NPV 
24 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
1. Influence of patient characteristics on diagnostic accuracy of Thermalytix©.
Patient characteristics will include:
(a) Age
(b) Lesion type
(c) Pathologic diagnosis
(d) Menopausal and hormonal status
(e) Breast density
(f) Family history
(g) Risk factors
2. Recommend how Thermalytix© can be used to complement standard breast cancer screening procedure.
 
24 weeks 
 
Target Sample Size   Total Sample Size="275"
Sample Size from India="275" 
Final Enrollment numbers achieved (Total)= "258"
Final Enrollment numbers achieved (India)="258" 
Phase of Trial   N/A 
Date of First Enrollment (India)   21/09/2017 
Date of Study Completion (India) 31/07/2018 
Date of First Enrollment (Global)  21/09/2017 
Date of Study Completion (Global) 31/07/2018 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Completed 
Recruitment Status of Trial (India)  Completed 
Publication Details    
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary
Modification(s)  

Breast cancer is one of the crucially prevailing cancers among women. Early detection and diagnosis of breast cancer is very important for patient survival. Currently, mammography is the most common method used for detection of breast cancer. However, mammography has certain limitations. It is not recommended to be used on women under the age of 45 years, cannot be used on lactating women and is inconclusive on women with high density of breast. Mammography in correlation with sono-mammography is widely used currently for screening in hospitals .

 

Infrared imaging of the breast or thermography is an imaging technique which detects suspected malignancy based on thermal changes on the chest. Due to increased blood circulation and metabolic activity of the tumour, the temperature of the tissue is higher around the regions where a tumor is present. A high resolution thermal camera can be used to capture this thermal information. This thermal image representing the temperature variations observed on the breast is called a breast thermogram. A thermal image provides a visual representation of the temperature distribution and can be used for clinical interpretation of abnormal breast conditions as an adjunct modality. Particularly, radiologists who are also certified thermologists are able to interpret these breast thermograms to determine its malignancy or benign condition.  However, manual interpretation of these themograms is very cumbersome and error prone.  Thermalytix is a new method of interpreting thermal images using CAD anovel Artificial Intelligence and Machine Learning Algorithms and has shown promising results in early experiments.

 

Our proposed research is to improve breast cancer screening through low cost, mobile, non-invasive and non-contact thermal screening without causing any discomfort to patients and develop accurate interpretation algorithms using machine learning, image processing and computer vision techniques to give automated screening capabilities.

 

In this study, sensitivity of Thermalytix© (an automated thermographic screening algorithms developed by NIRAMAI) will be compared to the sensitivity of standard screening modalities. The entry criteria for the study will be subjects who show possible symptoms of suspected breast cancer, such as pain, lump and so on.

 

The primary objectives of the study are to assess a non-inferiority of sensitivity of Thermalytix© methodology over the sensitivity of standard screening procedures by not more than 10% and study comparative diagnostic performance of Thermalytix© with standard screening modalities. The endpoint measurements would be sensitivity, specificity, PPV (Positive Predictive Values) and NPV (Negative Predictive Values) in the detection of breast cancer in women.

 

Secondary Objectives would be to study the influence of effects of patient characteristics on diagnostic accuracy. Patient characteristics would include, Age, Lesion type, Pathologic diagnosis, Menopausal and hormonal status, Breast density and Family history. Also to study how Thermalytix© can complement the standard modalities in breast cancer screening in future

 

This protocol for human research study will be conducted according to standards of effective Good Clinical Practice (International Conference on Harmonization (ICH) Guidelines), if applicable the Indian regulations and applicable Ethical Guidelines for Biomedical Research involving Human Participants issued by the Indian Council of Medical Research. The trial protocol and subject documentation will be reviewed and approved by the Institutional Ethical Review Boards of the participating trial sites.

 
Close